To disclose information that is material for the client to make an informed decision, including details of its business activity, disciplinary history, the terms and conditions of research services, details of associates, risks and conflicts of interest, if any.
To disclose the extent of use of Artificial Intelligence tools in providing research services.
To disclose, while distributing a third-party research report, any material conflict of interest of such third-party research provider or provide the web address that directs a recipient to the relevant disclosures.
To disclose any conflict of interest of the activities of providing research services with other activities of the Research Analyst.
To distribute research reports and recommendations to the clients without discrimination.
To maintain confidentiality with respect to publication of the research report until made available in the public domain.
To respect data privacy rights of clients and take measures to protect unauthorized use of their confidential information.
To disclose the timelines for the services provided by the Research Analyst to clients and ensure adherence to the said timelines.
To provide clear guidance and adequate caution notice to clients when providing recommendations for dealing in complex and high-risk financial products/services.
To treat all clients with honesty and integrity.
To ensure confidentiality of information shared by clients unless such information is required to be provided in furtherance of legal obligations or the client has provided specific consent to share such information.
Investor can lodge complaint/grievance against the Research Analyst in the following ways:
In case of any grievance/complaint, an investor may approach the concerned Research Analyst, who shall strive to redress the grievance immediately, but not later than 21 days from the date of receipt of the grievance.
SCORES (SEBI Complaints Redress System) is a web-based centralized grievance redressal system of SEBI.
Website:
https://scores.sebi.gov.in
Two-level review mechanism:
First Review – Research Analyst Administration and Supervisory Body (RAASB)
Second Review – SEBI
The investor may also email the designated email ID of RAASB.
If the investor is not satisfied with the resolution provided by the Market Participant, then the investor has the option to file the complaint/grievance on the SMART ODR Platform for resolution through online conciliation or arbitration.
For physical complaints, investors may send complaints to the registered office of the Research Analyst.
Right to Privacy and Confidentiality.
Right to Transparent Practices.
Right to Fair and Equitable Treatment.
Right to Adequate Information.
Right to Initial and Continuing Disclosure.
Right to receive all statutory and regulatory disclosures.
Right to Fair and True Advertisement.
Right to Awareness about Service Parameters and Turnaround Times.
Right to be informed of timelines for each service.
Right to be Heard and Satisfactory Grievance Redressal.
Right to timely redressal of complaints.
Right to Exit from Financial Products or Services in accordance with agreed terms.
Right to receive clear guidance and caution notices when dealing in complex and high-risk financial products and services.
Right to access services in a suitable manner even if differently abled.
Right to provide feedback on financial products and services.
Right against coercive, unfair and one-sided clauses in financial agreements.
Always deal with SEBI Registered Research Analysts.
Ensure that the Research Analyst holds a valid SEBI Registration.
Verify SEBI Registration before availing services.
Refer to the list of SEBI Registered Research Analysts available on the SEBI website.
Carefully read all disclosures made in research reports before investing.
Pay fees only through banking channels and preserve payment receipts.
Clients may pay fees through CeFCoM (where applicable).
Before buying or selling securities or applying in a public issue, review the recommendations provided by the Research Analyst.
Ask relevant questions and clarify all doubts before acting upon any recommendation.
Seek guidance from the Research Analyst, particularly while dealing with complex and high-risk financial products.
| Sr No | Received From | Pending at End of Last Month | Received | Resolved | Total Pending | Pending > 3 Months | Average Resolution Time (Days) |
|---|---|---|---|---|---|---|---|
| 1 | Directly from Investors | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | SEBI (SCORES) | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | Other Sources (if any) | 0 | 0 | 0 | 0 | 0 | 0 |
| GRAND TOTAL | 0 | 0 | 0 | 0 | 0 | 0 |
| Sr No | Month | Carried Forward | Received | Resolved | Pending |
|---|---|---|---|---|---|
| 1 | JAN 24 | 0 | 0 | 0 | 0 |
| 2 | FEB 24 | 0 | 0 | 0 | 0 |
| 3 | MAR 24 | 0 | 0 | 0 | 0 |
| 4 | APR 24 | 0 | 0 | 0 | 0 |
| 5 | MAY 24 | 0 | 0 | 0 | 0 |
| 6 | JUN 24 | 0 | 0 | 0 | 1 |
| 7 | JUL 24 | 0 | 0 | 2 | 0 |
| 8 | AUG 24 | 0 | 0 | 0 | 0 |
| 9 | SEP 24 | 0 | 0 | 0 | 0 |
| 10 | OCT 24 | 0 | 0 | 0 | 0 |
| 11 | NOV 24 | 0 | 0 | 0 | 0 |
| 12 | DEC 24 | 0 | 0 | 0 | 0 |
| 13 | JAN 25 | 0 | 0 | 0 | 0 |
| 14 | FEB 25 | 0 | 0 | 0 | 0 |
| 15 | MAR 25 | 0 | 0 | 0 | 0 |
| 16 | APR 25 | 0 | 0 | 0 | 0 |
| 17 | MAY 25 | 0 | 0 | 0 | 0 |
| 18 | JUN 25 | 0 | 0 | 0 | 0 |
| 19 | JUL 25 | 0 | 0 | 0 | 0 |
| 20 | AUG 25 | 0 | 0 | 0 | 0 |
| 21 | SEP 25 | 0 | 0 | 0 | 0 |
| 22 | OCT 25 | 0 | 0 | 0 | 0 |
| 23 | NOV 25 | 0 | 0 | 0 | 0 |
| 24 | DEC 25 | 0 | 0 | 0 | 0 |
| 25 | JAN 26 | 0 | 0 | 0 | 0 |
| 26 | FEB 26 | 0 | 0 | 0 | 0 |
| 27 | MAR 26 | 0 | 0 | 0 | 0 |
| 28 | APR 26 | 0 | 0 | 0 | 0 |
| 29 | MAY 26 | 0 | 0 | 0 | 0 |
| Sr No | Year | Carried Forward | Received | Resolved | Pending |
|---|---|---|---|---|---|
| 1 | 2018–19 | NOT APPLICABLE | NOT APPLICABLE | NOT APPLICABLE | NOT APPLICABLE |
| 2 | 2019–20 | NOT APPLICABLE | NOT APPLICABLE | NOT APPLICABLE | NOT APPLICABLE |
| 3 | 2020–21 | NOT APPLICABLE | NOT APPLICABLE | 0 | 0 |
| 4 | 2021–22 | NOT APPLICABLE | NOT APPLICABLE | 0 | 0 |
| 5 | 2022–23 | 0 | 0 | 0 | 0 |
| 6 | 2023–24 | 0 | 0 | 0 | 0 |
| 7 | 2024–25 | 0 | 0 | 0 | 0 |
| 8 | 2025–26 (Up to May 2026) | 0 | 0 | 0 | 0 |
| GRAND TOTAL | 0 | 0 | 0 | 0 |
Warning : Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer: Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
